Effector phenotype and immunologic specificity of T cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity
- 1 August 1990
- journal article
- research article
- Published by Elsevier in Cellular Immunology
- Vol. 129 (1) , 241-255
- https://doi.org/10.1016/0008-8749(90)90201-2
Abstract
No abstract availableThis publication has 51 references indexed in Scilit:
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells.The Journal of Experimental Medicine, 1985
- Characterization of the Murine Antigenic Determinant, Designated L3T4a, Recognized by Monoclonal Antibody GK 1.5: Expression of L3T4a by Functional T Cell Clones Appears to Correlate Primarily with Class II MHC Antigen‐ReactivityImmunological Reviews, 1983
- Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes.The Journal of Experimental Medicine, 1981
- Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes.The Journal of Experimental Medicine, 1980
- The questionable immunogenicity of certain neoplasmsCancer Immunology, Immunotherapy, 1977
- Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donorsInternational Journal of Cancer, 1972
- A generalized Wilcoxon test for comparing arbitrarily singly-censored samplesBiometrika, 1965
- TREATMENT OF PRIMARY FIBROSARCOMA IN THE RAT WITH IMMUNE LYMPHOCYTESThe Lancet, 1964
- STUDIES ON THE IMMUNOLOGICAL RESPONSE TO FOREIGN TUMOR TRANSPLANTS IN THE MOUSEThe Journal of Experimental Medicine, 1955